KAREN J WILSON
CIK 1267490 · SVP, Finance & PAO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.80M
Companies
7
Total Filings
59
Lifetime Open-Market Net
-$11.47M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SER | Director | 30,100 | $2.05 | $61.7K | $54.7K | 5 | 2026-06-22 |
| LAVA Therapeutics NV (LVTX) Delisted | Director | 0 | $1.74 | $0 | $0 | 2 | 2025-11-17 |
| ELTX | Director | — | $2.90 | — | $0 | 3 | 2025-05-20 |
| Elicio Therapeutics, Inc. (ANGN) Delisted | Director | 1,872 | $10.00 | $18.7K | $0 | 3 | 2022-06-13 |
| Vaxart, Inc. (VXRT) Delisted | Director | — | $0.32 | — | $0 | 2 | 2021-06-17 |
| JAZZ | SVP, Finance & PAO | 18,385 | $257.70 | $4.74M | -$11.52M | 43 | 2019-03-07 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | VP of Finance & PAO | 10,494 | — | — | $0 | 1 | 2009-05-11 |
Recent Filings · Page 2 of 6
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-13 | Elicio Therapeutics, Inc. (ANGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-17 | Vaxart, Inc. (VXRT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-10 | Elicio Therapeutics, Inc. (ANGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-11 | Elicio Therapeutics, Inc. (ANGN) Delisted | Conv (C) | +18,718 | $216.6K | EDGAR |
| 2020-08-27 | Vaxart, Inc. (VXRT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-07 | JAZZ | Tax (F) | −578 | -$78.5K | EDGAR |
| 2019-03-04 | JAZZ | Grant (A) | +3,500 | $0 | EDGAR |
| 2019-02-27 | JAZZ | Tax (F) | −540 | -$68.5K | EDGAR |
| 2018-05-15 | JAZZ | Sell (S) | −3,760 | -$620.4K | EDGAR |
| 2018-04-12 | JAZZ | Sell (S) | −3,899 | -$604.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.